Advertisement

Crohn’s fistula: current concepts in management1

  • Daniel H. Present
    Correspondence
    Address requests for reprints to: Daniel H. Present, M.D., Mount Sinai School of Medicine, 12 East 86th Street, New York, New York 10028-0517, USA; fax: (212) 628-3648
    Affiliations
    Mount Sinai School of Medicine, New York, New York, USA
    Search for articles by this author
      Crohn’s disease was described in 1932 in the classic article by Crohn et al., and then subsequently the authors described one of the disease complications, namely perianal fistula. It was originally thought that the perianal disease originated in the inflamed terminal ileum, which extended internally down to the perianal area. In the last 70 years, we have learned much about this disease, as well as the complications of both perianal and internal fistula. Approximately 60%–70% of all patients with Crohn’s disease will eventually need to undergo surgery, which in many cases is related to the development of a perianal fistula, subsequent to an abscess.
      • Glotzer D.J.
      Surgical therapy for Crohn’s disease.
      The purpose of this article is to review our current knowledge of Crohn’s fistula, focusing predominantly on the concepts in clinical management.
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Glotzer D.J.
        Surgical therapy for Crohn’s disease.
        Gastroenterol Clin North Am. 1995; 24: 577-596
        • Allan A.
        • Keighley R.B.
        Management of perianal disease.
        World J Surg. 1988; 12: 198-202
        • Givel J.C.
        • Hawker P.
        • Allan R.
        • Alexander-Williams J.
        Entero-enteric fistula complicating Crohn’s disease.
        J Clin Gastroenterol. 1983; 5: 321-323
        • Schwartz D.A.
        • Loftus Jr, E.V.
        • Tremaine W.J.
        • Panaccione R.
        • Harmsen W.S.
        • Zinsmeister A.R.
        • Sandborn W.J.
        The natural history of fistulizing Crohn’s disease in Olmstead County, Minnesota.
        Gastroenterology. 2002; 122: 875-880
        • Hellers G.
        • Bergstrand O.
        • Ewerth S.
        • Holmstrom B.
        Occurrence in outcome after primary treatment of anal fistulae in Crohn’s disease.
        Gut. 1980; 21: 525-527
        • D’Haens G.
        Medical management of internal fistulae in Crohn’s disease.
        Inflamm Bowel Dis. 2003; 6: 244-245
        • Aeberhard P.
        • Berchtold W.
        • Riedtmann H.J.
        • Stadelmann G.
        Surgical recurrence of perforating and non-perforating Crohn’s disease—a study of surgically treated patients.
        Dis Colon Rectum. 1996; 39: 80-87
        • Parks A.G.
        • Gordon P.H.
        • Hardcastle J.D.
        A classification of fistula-in-ano.
        Br J Surg. 1976; 63: 1-12
        • Schwartz D.A.
        • Pemberton J.H.
        • Sandborn W.J.
        Diagnosis and treatment of perianal fistulas in Crohn disease.
        Ann Intern Med. 2001; 135: 906-918
        • Schwartz D.A.
        • Wiersema M.J.
        • Dudiak K.M.
        • Fletcher J.G.
        • Clain J.E.
        • Tremaine W.J.
        • Zinsmeister A.R.
        • Norton I.D.
        • Baardman L.A.
        • Devine R.M.
        • Wolff B.G.
        • Young-Fadok T.M.
        • Dehl N.N.
        • Pemberton J.U.
        • Sandborn W.J.
        A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas.
        Gastroenterology. 2001; 121: 1064-1072
        • Hamalainen K.-P.J.
        • Sainio A.P.
        Incidence of fistulas after drainage of acute anorectal abscesses.
        Dis Colon Rectum. 1998; 41: 1357-1362
        • Makowiecs J.O.
        • Jehle B.C.
        • Becker H.D.
        • Starlinger M.
        Perianal abscess in Crohn’s disease.
        Dis Colon Rectum. 1997; 40: 443-450
        • Sohn N.
        Selected summaries.
        Inflamm Bowel Dis. 1998; 4: 257
        • Williams J.G.
        • Rothenberger D.A.
        • Nemer F.D.
        • Goldberg S.M.
        Fistula-in-ano in Crohn’s disease with results of aggressive surgical treatment.
        Dis Colon Rectum. 1991; 34: 378-384
        • Present D.H.
        How to do without steroids in inflammatory bowel disease.
        Inflamm Bowel Dis. 2000; 6: 48-57
        • Present D.H.
        Urinary tract fistulas in Crohn’s disease.
        Am J Gastroenterol. 2002; 97: 2165-2167
        • Ursing B.
        • Kamme C.
        Metronidazole for Crohn’s disease.
        Lancet. 1975; 1: 775-777
        • Sutherland L.
        • Singleton J.
        • Sessions J.
        • Hanauer S.
        • Krawitt E.
        • Rakin G.
        • Summers R.
        • Mekhjian N.
        • Greenberger N.
        • Kelly M.
        • Levine J.
        • Thomson A.
        • Alpert E.
        • Prokipchu K.
        Double blind placebo control trial of metronidazole in Crohn’s disease.
        Gut. 1991; 32: 1071-1075
        • Bernstein L.H.
        • Frank M.S.
        • Brandt L.J.
        • Boley S.J.
        Healing of perineal Crohn’s disease with metronidazole.
        Gastroenterology. 1987; 79: 357-365
        • Colombel J.F.
        • Lemann M.
        • Cassagnou M.
        • Scuhnik Y.
        • Duclos B.
        • Notteghem B.
        • GETAID
        A control trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease.
        Am J Gastroenterol. 1999; 94: 674-678
        • Turunen U.M.
        • Farkkila M.
        • Valtone N.
        Long-term outcome of ciprofloxacin in the treatment of severe perianal or fistulous Crohn’s disease.
        Gastroenterology. 1993; 104A (abstr): 793
        • Solomon M.J.
        Combination of ciprofloxacin and metronidazole in severe perianal Crohn’s disease.
        Can J Gastroenterol. 1993; 7: 571-573
        • Present D.H.
        • Korelitz B.I.
        • Wisch N.
        • Glass J.L.
        • Sachar D.G.
        • Pasternack B.S.
        Treatment of Crohn’s disease with 6 Mercaptopurine. A long term randomized double blind study.
        N Engl J Med. 1980; 302: 981-987
        • Korelitz B.I.
        • Present D.H.
        The favorable effects of 6 mercaptopurine in the fistulous Crohn’s disease.
        Dig Dis Sci. 1985; 30: 58-64
        • Pearson D.C.
        • May G.R.
        • Fick G.H.
        • Sutherland L.R.
        Azathioprine and 6 mercaptopurine in Crohn’s disease—a meta-analysis.
        Ann Intern Med. 1995; 123: 132-142
        • Muhadevan U.
        • Marion J.
        • Present D.H.
        The price of methotrexate in the treatment of refractory Crohn’s disease.
        Gastroenterology. 1997; 112A (abstr): 1031
        • Present D.H.
        • Lichtiger S.
        Efficacy of cyclosporin in the treatment of fistula of Crohn’s disease.
        Dig Dis Sci. 1994; 39: 374-380
        • Lowery P.W.
        • Weaver A.L.
        • Tremaine W.J.
        • et al.
        Combination therapy with oral Tacrolimus (FK506) and Azathioprine with 6 Mercaptopurine for treatment refractory Crohn’s disease perianal fistula.
        Inflamm Bowel Dis. 1999; 5: 239-245
        • Sandborn W.J.
        Preliminary report on the use of oral Tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease.
        Am J Gastroenterol. 1997; 92: 876-879
        • Sandborn W.J.
        • Present D.H.
        • Isaacs K.L.
        • Wolf D.R.
        • Greenberg E.
        • Hanauer S.B.
        • Feacan B.G.
        • Johnson T.
        • Galanka J.
        • Martin C.
        • Sandler R.S.
        Tacrolimus (FK506) for the treatment of perianal and enterocutaneous fistulas in patients with Crohn’s disease.
        Gastroenterology. 2003; 124 (in press)
        • Present D.H.
        • Rutgeerts P.
        • Targan S.
        • Hanauer S.B.
        • Mayer L.
        • Van Hogezand R.A.
        • Podolsky D.K.
        • Sands B.E.
        • Braakman T.
        • DeWoody K.L.
        • Schaible T.F.
        • Van Deventer S.J.I.
        Infliximab for the treatment of fistulas in patients with Crohn’s disease.
        N Engl J Med. 1999; 340: 1398-1405
        • Sandborn W.J.
        • Hanauer S.D.
        Infliximab in the treatment of Crohn’s disease. A user’s guide for clinicians.
        Am J Gastroenterol. 2002; 97: 2962-2972
        • Sands B.
        • Vandeventer B.
        • Bernstein C.
        • et al.
        Long-term treatment of fistulizing Crohn’s disease.
        Gastroenterology. 2002; 122 (abstr): A8l
        • Sandborn W.J.
        • Feagan S.C.
        • Hanauer S.B.
        • Present D.H.
        • Sutherland L.R.
        • Komm M.K.
        • Wolf D.C.
        • Baker J.P.
        • Hawkey C.
        • Archamboult N.
        • Bernstein C.N.
        • Novak C.
        • Targan S.R.
        An engineered human antibody TΔTNF(CDP 571) for active Crohn’s disease.
        Gastroenterology. 2001; 120: 1330-1338
        • Ochsenkuhn T.
        • Goke B.
        • Sackmann M.
        Combining Infliximab with 6 Mercaptopurine/Azathioprine for fistula therapy in Crohn’s disease.
        Am J Gastroenterol. 2002; 97: 2022-2025
        • Wheeler C.
        • Marion J.F.
        • Present D.H.
        Medical therapy, not surgery, is the appropriate first line treatment of Crohn’s enterovesical fistula (abstr).
        Gastroenterology. 1998; 114A: 1113
        • Sonoda T.
        • Haull T.
        • Piedmonte M.R.
        • Fazi V.
        Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap.
        Dis Colon Rectum. 2002; 45: 1622-1628
        • Ky A.
        • Sohn N.
        • Weinstein M.A.
        • Conners Jr, A.F.
        Carcinoma arising in anorectal fistulas of Crohn’s disease.
        Dis Colon Rectum. 1998; 41: 992-996
        • Arsenau K.O.
        • Cohn S.M.
        • Cominelli F.
        • Korelitz B.I.
        Cost-utility as initial medical management for Crohn’s disease perianal fistulae.
        Gastroenterology. 2001; 120: 1640-1656
        • Baert F.
        • Noman M.
        • Vermeire S.
        • Van Assgie G.
        • D’Haens G.
        • Carbonez A.
        • Rutgeerts P.
        Influence of immunogenicity on the long term efficacy of Infliximab in Crohn’s disease.
        N Engl J Med. 2003; 348: 601-608